Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Corifollitropin alfa versus modified natural cycles in poor ovarian responders undergoing ART
2021-001835-22Phase 4Active
- Sponsor
- Ghent University Hospital
- Start
- Jul 2021
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of corifollitropin alfa, follitropin beta, ganirelix and human chorionic gonadotropin in female infertility and poor ovarian response (POR) (2 arms), sponsored by Ghent University Hospital. Started Jul 2021; status: active.
02
Drugs
corifollitropin alfafollitropin betaganirelixhuman chorionic gonadotropin
03
Conditions
female infertilitypoor ovarian response (POR)
Beyond the preview
Go deeper on 2021-001835-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001835-22.